Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours

XR11576 is an oral topoisomerase I and II inhibitor. The objectives of this phase I study were to assess the dose-limiting toxicities (DLTs), to determine the maximum tolerated dose (MTD) and to describe the pharmacokinetics (PKs) of XR11576 when administered orally on days 1–5 every 3 weeks to pati...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jonge, M J A, Kaye, S, Verweij, J, Brock, C, Reade, S, Scurr, M, van Doorn, L, Verheij, C, Loos, W, Brindley, C, Mistry, P, Cooper, M, Judson, I
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409936/
https://www.ncbi.nlm.nih.gov/pubmed/15452551
http://dx.doi.org/10.1038/sj.bjc.6602178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409936/
https://www.ncbi.nlm.nih.gov/pubmed/15452551
http://dx.doi.org/10.1038/sj.bjc.6602178

Ejemplares similares